

CBD and PSP cell-passaged Tau Seeds Generate Heterogeneous Fibrils with A sub-population Adopting Disease Folds

Zhikai Zeng¹, Vishnu Vijayan¹, Karen Tsay¹, Matthew P. Frost², Athena Quddus³, Alexa Albert⁴, Michael Vigers⁵, Amanda L. Woerman^{2*} and Songi Han^{1,5*}

¹Department of Chemistry and Biochemistry, University of California Santa Barbara, Santa Barbara, 93105, CA, USA.

²Department of Biology and Institute for Applied Life Sciences, University of Massachusetts Amherst, Amherst, 01003, MA, USA.

³Department of Molecular, Cellular, and Developmental Biology, University of California Santa Barbara, Santa Barbara, 93105, CA, USA.

⁴Department of Psychological and Brain Sciences, University of California Santa Barbara, Santa Barbara, 93105, CA, USA.

⁵Department of Chemical Engineering, University of California Santa Barbara, Santa Barbara, 93105, CA, USA.

*Corresponding author(s). E-mail(s): awoerman@umass.edu; songihan@ucsb.edu;

Contributing authors: zeng@ucsb.edu; vishnu@umail.ucsb.edu; tsay@ucsb.edu; mfrost@uchc.edu; aquddus@ucsb.edu; alexacalbert@ucsb.edu; mvigiers@ucsb.edu;

Abstract

The recent discovery by cryo-electron microscopy that the neuropathological hallmarks of different tauopathies, including Alzheimer's disease, corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP), are caused by unique misfolded conformations of the protein tau is among the most profound developments in neurodegenerative disease research. To capitalize on these discoveries for therapeutic development,

one must achieve *in vitro* replication of tau fibrils that adopt the representative tauopathy disease folds - a grand challenge. To understand whether the commonly used, but imperfect, fragment of the tau protein, K18, is capable of inducing specific protein folds, fibril seeds derived from CBD- and PSP-infected biosensor cells expressing K18, were used to achieve cell-free assembly of naïve, recombinant 4R tau into fibrils without the addition of any cofactors. Using Double Electron Electron Resonance (DEER) spectroscopy, we discovered that cell-passaged pathological seeds generate heterogeneous fibrils that are distinct between the CBD and PSP lysate-seeded fibrils, and are also unique from heparin-induced tau fibril populations. Moreover, the lysate-seeded fibrils contain a characteristic sub-population that resembles either the CBD or PSP disease fold, corresponding with the respective starting patient sample. These findings indicate that CBD and PSP patient-derived fibrils retain strain properties after passaging through K18 reporter cells.

Keywords: Tau, seeding, strains, structure, DEER

1 Introduction

Tauopathies are a varied group of neurodegenerative diseases defined by the deposition of fibrillar aggregates of the microtubule-binding protein tau (MAPT, or tau) in the brain. Notably, the prevalence of these deposits is closely related to clinically observable neurodegeneration [1, 2]. In the disease state, tau misfolds from a soluble monomer into an insoluble fibril with a β -sheet-rich structure capable of recruiting naïve tau to self-replicate, consistent with the prion mechanism of disease. Although tau pathologies specific to each disease vary in morphology and isoform composition [3], the defining difference between the clinical phenotypes is now thought to arise from the shape, or conformation, that tau adopts. This is the basis of the strain hypothesis or the idea that protein conformation determines disease [4–6].

In 2013, the Goedert lab showed that brain homogenates prepared from a variety of deceased tauopathy patient samples, including progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and argyrophilic grain disease (AGD), induced tau pathology following intracerebral injection into a transgenic mouse model expressing human tau [7]. The induced inclusions exhibited immunostaining patterns similar to those seen in the corresponding human pathology, suggesting that each disease may be caused by a distinct tau strain [7, 8]. Subsequent work investigating tau strain biology employed cell models expressing the microtubule-binding repeat domain of tau, including the fragment spanning residues 244–368 known as K18, with a C-terminal fluorescent reporter protein [9–11]. These studies determined that tau strains are distinct with respect to the seeding capacity, isoform involvement, cell-type specificity, and protease digestion or guanidine denaturation patterns [9–16]. However, research on tau strains was truly revolutionized by advances

in cryo-electron microscopy (cryo-EM), resulting in the resolution of tau folds present in several tauopathies, including Alzheimer’s disease (AD) [17], Pick’s disease, [18], CBD [19, 20], chronic traumatic encephalopathy (CTE) [21], PSP [22, 23], AGD [23], and globular glial tauopathy (GGT) [23] patient samples. This important body of work has shown that underlying each tauopathy is a distinct conformation of misfolded tau.

Recombinant tau fibrils induced by polyanionic cofactors, such as heparin, were commonly used to study tau aggregation [24], but cryo-EM [25] and Double Electron Electron Resonance (DEER) [26] have revealed that cofactor-induced fibrils are heterogeneous and distinct from patient-derived fibrils and are thus not disease relevant. This indicates a need for developing accessible and reliable methods for replicating disease folds. Previous studies have shown that patient-derived fibrils could be propagated in cell-free or *in vitro* systems, as evidenced by the similar morphological and biochemical properties between the tau seeds and resulting fibrils [13, 14, 27–33]. However, whether or not the atomic conformational features of the disease folds are conserved and replicated has not been investigated to date. We, therefore, set out to test the widely assumed hypothesis that patient-derived fibrils induce tauopathy-specific protein misfolding of recombinant tau monomer after passing through K18 reporter cells, with biophysical tools. While cryo-EM and solid-state NMR have been crucial for unraveling the atomic basis of tau strains at high-resolution, these are not suitable tools to capture dynamically evolving and long-range intra-tau distances, nor are they sufficient for studying a heterogeneous fibril population. In order to study *whether* and *how* tau fibrillar seeds template protein misfolding in a strain-specific manner at sufficiently high-resolution to differentiate between key disease folds, a structural biology tool is needed that can capture conformations of disordered and partially disordered fibril regions and report on the distribution of heterogeneous fibril populations. Double Electron Electron REsonance (DEER), a pulsed dipolar electron paramagnetic resonance (EPR) spectroscopic method, is such a tool capable of reporting on the distribution of conformations of doubly spin-labeled proteins regardless of its order and disorder, and hence capture the complete population of tau fibrils formed upon seeded aggregation using CBD and PSP patient-derived materials.

In this study, we isolated tau fibrils from post-mortem CBD and PSP patient samples, which we used to establish monoclonal Tau4RD*LM-YFP cell lines, also referred to as biosensor cell lines, that stably propagate either CBD or PSP patient-derived fibrils, as shown in Fig. 1a. Lysates collected from these cells were then added to recombinant tau monomer, either Tau187 (residues 255-441) or the 0N4R tau isoform, to seed protein misfolding. DEER was used to measure the probability distribution, $P(r)$, of intramolecular distances r , from 1.5 to several nm ranges across a pair of spin-labels, both attached to the same tau molecule. We carefully selected three spin-label pairs to capture distances across tau segments specific to CBD and PSP folds - residues 351 & 373, 334 & 360, and 340 & 378 (illustrated in Fig. 1b). A similar approach of

relying on select spin label pairs on tau molecules to evaluate the protein fold of tau stacked into fibrils has been demonstrated in earlier studies [26, 34, 35]. The theoretical distance distribution for the above-listed spin-label pairs on the reported CBD and PSP folds is computed with the RotamerConvolveMD method [36] (shown in Fig. 1c). The doubly spin-labeled tau was diluted with unlabeled, cysteine-less, tau in order to capture intra-molecular distances that are sensitive to the fold of the tau protein stacked into fibrils, and not to inter-molecular distances that are sensitive to the fibril packing order. We compared the measured $P(r)$ with the simulated $P(r)$ based on the cryo-EM structures of CBD and PSP tau to understand whether fibrils seeded with cell-passaged CBD and PSP tau fibrils are conformationally distinct from each other, and from heparin-induced fibrils. Moreover, we set out to discover whether a sub-population of the heterogeneous fibril mixture represents inter-molecular tau distances contained in the CBD and PSP disease folds. Given that 1) CBD and PSP patient-derived fibrils are used to induce disease-relevant protein misfolding of K18 tau that is shorter than the sequence making up the core of the CBD and PSP fibril, 2) no cofactors were used, 3) no post-translational modifications were included, and 4) the experiments were performed in a cell-free system, the answers to the posed questions were not obvious.

2 Results

2.1 Cell-passaged CBD and PSP lysates template recombinant tau misfolding and aggregation

To investigate tau misfolding in CBD and PSP, we first established Tau4RD*LM-YFP cells that stably propagate pathogenic tau isolated from brain samples received from deceased CBD and PSP patients (schematically shown in Fig. 1a). Using similar methods as previously described [11], tau prions were isolated from one control, one CBD, and one PSP brain homogenate with sodium phosphotungstate (PTA) that selectively precipitates insoluble protein aggregates [37, 38]. The resulting protein pellets were then resuspended in DPBS and incubated with either Tau3RD*VM-YFP cells or Tau4RD*LM-YFP cells for 4 days. Consistent with our previous findings [37], the CBD and PSP patient samples induced tau misfolding and aggregation in the Tau4RD*LM-YFP cells, but had no effect on the Tau3RD*VM-YFP cell line (Fig. 2a & b). We then generated monoclonal cell lines that stably propagate either CBD or PSP tau via single-cell plating of infected cells. Expression levels of the 4RD-YFP construct were confirmed via Western blot using lysate collected in RIPA buffer (Fig. 2c).

For seeding experiments, lysates from Tau4RD*LM-YFP cells infected with CBD and PSP patient samples were collected in 1X protease inhibitor and were further diluted in 20 mM HEPES buffer (pH 7.4) to 5% to 15% (protein mass percentage) to seed the fibrillization of recombinant Tau187. The two naturally occurring cysteines in this construct were mutated to serines (C291S and C322S) to avoid the formation of disulfide bonds that are known to not be part

of pathological tau fibril folds [19, 21], and instead may inhibit tau aggregation [39]. To determine if the cell-passaged lysates can induce the fibrillization of tau, thioflavin T (ThT) fluorescence measurements were collected over the course of 24 hours. ThT is a fluorescent dye that binds specifically to β -sheet structures of amyloid proteins [40] and provides an *in situ* assessment of β -sheet abundance. The cell-passaged CBD and PSP lysates induced a robust increase in ThT fluorescence of Tau187 in a concentration-dependent manner (fluorescence intensity increased when 15% lysate was used compared to 5%; Fig. 3a). Not surprisingly, when polydisperse heparin (average molecular mass 15 kDa, Galen Lab Inc.) was added to the recombinant tau at a tau:heparin molar ratio of 4:1 (equivalent to 17% heparin by mass), heparin induced greater fibril quantities than the CBD or PSP lysates, as assessed by a significantly greater increase in the ThT max fluorescence emission ($*** = P < 0.001$). The cell-passaged lysates were also used to successfully seed the fibrillization of recombinant full-length (FL) 0N4R tau, but again less than what heparin induced as determined via ThT fluorescence (Fig. S1). We focused on Tau187 in the subsequent experiments as it has a more robust aggregation propensity compared to FL 0N4R tau. Tau187 contains the entire K18 sequence, as well as all regions included in the CBD and PSP fibril cores, and hence is ideally suited to study the seeded aggregation by cell-passaged CBD or PSP lysates.

To ensure that the measured fluorescence increase in the ThT assay was due to the formation of tau fibrils rather than soluble molecules in the cell-passaged seeds, we pelleted the tau aggregates from the lysates by ultracentrifugation at $100,000 \times g$ for 1 hour at 4°C , removing any soluble small molecule species in the supernatant. The remaining tau fibrils were then resuspended in 20 mM HEPES buffer (pH 7.4) and used to seed recombinant Tau187 fibrillization. ThT fluorescence showed that the pelleted samples induced fibrillization, whereas the supernatant did not (Fig. S2). Moreover, the isolated fibrils and clarified lysates induced comparable fluorescence plateaus, indicating that the seeding capacity of the cell-passaged fibrils originates from the aggregated insoluble tau, not soluble species in the lysates. We can conclude that the cell-passaged fibrils induce recombinant tau misfolding and fibrillization, and the kinetics of this process are influenced by the quantity of the seed used. To maximize the seeded fibril quantity, 15% cell-passaged seeds were used in subsequent experiments.

The morphologies of the heparin-induced and lysate-seeded fibrils were characterized by negative stain Transmission Electron Microscopy (TEM). As shown in Fig. 3b, heparin-induced fibrils were predominantly long, straight, and well-separated from one another with a few of the fibrils exhibiting a wavy appearance. We also observed long and straight, but more associated, fibrils for both CBD and PSP lysate-seeded fibrils. The CBD lysate-seeded fibrils have a diameter of 20 nm and are devoid of any helical twists. Earlier reports suggest that CBD fibrils are heterogeneous, containing both narrow, straight fibrils and wider, twisted, ribbon-like fibrils [41–43]. The morphology we observe in this study is closer to the narrow, straight filaments reported for

CBD [19]. The TEM images of PSP-induced fibrils showed fibrils with a very similar appearance, featuring slightly smaller diameter fibrils (16-18 nm) with the appearance of straight tubules, in agreement with the previous reports of brain-derived PSP fibril morphology.[42, 43]

To determine if the heparin-induced and lysate-seeded fibrils exhibit prion activity, we incubated both the Tau3RD*VM-YFP and Tau4RD*LM-YFP cells with all three fibril types, as well as monomeric Tau187. Indeed, all three fibrils induced tau aggregation in the Tau4RD*LM-YFP cells but had no effect on the Tau3RD*VM-YFP cells (Fig. 3c & d). In contrast, monomeric Tau187 had no effect in either cell line tested.

2.2 CBD and PSP lysate-seeded tau fibrils have distinct conformations with sub-populations that recapitulate the disease-specific folds

Although cryo-EM tau structures [19–23, 23, 44] have rightfully captured the field’s attention, cryo-EM can only resolve a homogeneous fibril population from brain samples after extensive purification of fibrils from large quantities of brain material. Moreover, only large, detergent-insoluble fibrils have been successfully imaged, which may not include critical intermediates *en route* to pathological tau aggregation. In contrast, DEER spectroscopy provides an efficient and direct approach to characterize partially ordered and/or heterogeneous fibrils, or even of disordered proteins and partially aggregated proteins. It resolves the probability distribution of intra-molecular distances in the 1.5 to 8 nm ranges across a pair of spin-labels attached to a single tau molecule. Therefore, DEER can be used for discovery work on heterogeneous samples or to capture transient conformational ensembles populated along the pathway of seeded aggregation. After the conditions for structural convergence are achieved, guided by DEER studies, cryo-EM or other higher-resolution structural biology tools can be used to characterize the end product.

Consistently distinct fibril morphologies observed by negative stain TEM may have different underlying protein folds. However, there are many examples where similar protein folds give rise to distinct fibril morphologies, presumably due to differences in quaternary packing of protofibrils along the fibril axis or inter-fibril interactions, to name a few factors [17, 19, 45]. Some studies have shown different protein folds give rise to indistinguishable fibril morphologies [20].

Hence, protein folds within a fibril need to be directly measured. To investigate the conformational features of the lysate-seeded fibrils, we employed DEER to measure the distribution of intra-tau distances. DEER has the unique ability to measure the distribution of distances between a pair of electron spin-labels covalently tethered to tau at two sites modified by site-directed mutagenesis to cysteines. DEER is also solely sensitive to paramagnetic probes such as MTSL [S-(1-oxyl-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl methanesulfonothioate] and is not affected by the disorder or size of

the protein, and hence it is particularly well suited for tracking protein aggregation. In contrast, the effects of protein crowding, sample heterogeneity, and protein intrinsic disorder render the use of NMR, crystallography, or cryo-EM challenging or infeasible. Previously, we presented DEER-derived distance distributions from pairwise spin-labeled tau stacked to fibrils induced by the addition of the cofactor heparin, and found that these fibrils are structurally heterogeneous, judging by the width of the intra-tau distance distribution, $P(r)$. These structures were found to be clearly distinct from the tau fibrils present in AD patient samples by comparing the theoretical distance distribution for spin-label pairs on the reported AD fold with the experimentally measured one [26]. This result was subsequently confirmed with cryo-EM structures of heparin-induced tau fibrils that revealed a complete lack of homology between the heparin-induced and patient-derived fibrils [25].

In this study, we followed a similar procedure as reported in Fichou *et al.* [26], rationally selecting the spin-label pairs to be positioned along the outer layer of the fibril cores of the CBD and PSP folds and could be used to differentiate between CBD and PSP folds, based on the cryo-EM structures [19, 21]. Critically, we selected spin-label pairs that yield significantly different $P(r)$ between the monomeric and aggregated state (Fig. S4), to ensure that the change of the mean distance and distance distribution can unambiguously report on tau misfolding. All labeled sites were chosen due to their location outside of the heparin-induced fibril core as identified by cryo-EM [25] and hence should differentiate between heparin-induced and patient-derived structures.

After selecting our spin-label pairs, we introduced two cysteines into Tau187 at these desired sites by site-directed mutagenesis and spin-labeling (SDSL) of MTSL to the cysteine residues [46, 47]. To ensure that DEER measurements capture intramolecular (not intermolecular) distances, we diluted the doubly spin-labeled Tau187 with unlabeled Tau187 (i.e., without mutation to cysteines, and hence also no labels) to get spin-diluted Tau187 (10% doubly spin-labeled Tau187 + 90% unlabeled Tau187), such that statistically the closest distances are from the pair of spin-labels attached to the same Tau187 molecule. Effects from longer inter-molecular distances between spin-labels are corrected by subtracting a background function from the time-domain DEER decay that is modulated by the weaker, intermolecular, spin-spin interactions. Seeding assays conducted using spin-diluted Tau187 yielded similar ThT fluorescence intensity profiles as the aggregation assay using unlabeled Tau187 alone (Fig. S5). To prepare samples for DEER measurements, we added heparin or 15% lysates, respectively, to induce aggregation for 24 h. Samples were then subjected to dialysis (molecular weight cut off 25 kDa) against a D_2O buffer with 20 mM HEPES to remove excess monomer and to reduce 1H concentration to aid DEER measurements. We then derived the distribution of intra-tau spin-label distance, $P(r)$, from the experimental time-domain DEER data, $V(t)$, which is modulated by convolved dipolar coupling frequencies between pairs of spin-labels. The reconstruction of the distance distribution, $P(r)$ from $V(t)$ was determined using the recently published DeerLab fitting

algorithm and software.[48] 95% confidence intervals was determined by using the bootstrapping method with a sample size of 100.

The DEER-derived distance distributions for three spin-label pairs on heparin-induced fibrils and the CBD and PSP lysate-seeded fibrils were compared with the simulated DEER distance distributions expected from the reported cryo-EM CBD and PSP folds (Fig. 4). The distance distributions across the spin-label pair across residues 351 & 373, referred to as $P(r, 351-373)$, of the three different samples, are shown in Fig. 4a. The heparin fibrils (green) yielded the broadest distance distribution, which is distinct from the CBD (pink) and PSP lysate-seeded fibrils (blue). These results clearly demonstrate that the heparin fibrils are structurally unique and are more heterogeneous in the MTB region of the protein spanning residues 351-373. In contrast, the CBD and PSP lysate-seeded fibrils (in green and pink) exhibited a distinct shape for the distribution of the 351-373 distance, $P(r, 351-373)$, featuring two dominant distance features with narrower widths compared to that of heparin fibrils, suggesting that multiple and distinct populations of ordered tau conformers are present.

Despite the complexity of the observed $P(r)$ shape, the pattern of these peaks representing the CBD vs PSP lysate-seeded fibrils are highly reproducible. Each $P(r)$ was measured in triplicate, all data shown in Fig. S6 - 8, showcasing remarkable reproducibility between the repeats. The triplicates can be viewed, on the one hand, as technical replicates in terms of patient source, considering that one CBD and one PSP patient sample was used to generate CBD and PSP cell-passaged seeds. On the other hand, the seeds were derived from multiple cellular batches prepared at different times spanning multiple years, and the lysate-seeded samples were derived from at least three different *in vitro* seeding experiments performed on different batches of recombinant Tau187 and using biologically different cell-passaged seeds. The repeats can hence also be viewed as biological triplicates in terms of the cell-passaged seeds and lysate-seeded tau fibrils. Critically, the shape for $P(r)$ is clearly distinct between the CBD and PSP lysate-seeded fibrils. These results reveal that the cell-passaged seeds play an active role in templating and misfolding tau, with the two seeds inducing unique patterns for $P(r)$. An equally important observation is that each distinct pattern of $P(r)$ is still broad, suggesting that the templating induced by seeding does not generate converged fibril structures with the commonly used seed material and seeding protocol by many researchers. Critically, a dominant peak near the predicted spin-label distance (indicated by dotted lines) suggests that a sub-population of fibrils resembling the CBD and PSP disease folds may have formed. Specifically, a mean distance of 6.5 nm is expected for the CBD fold, while a dominant experimental peak is found at distances of 5-7 nm. In contrast, a mean distance of 3 nm is expected for the PSP fold, and again, one of the dominant experimental peaks is found spanning distances of 2-4 nm. Notably, this intensity at 2-4 nm is missing in the $P(r, 351-373)$ for the CBD lysate-seeded tau fibril population.

We next analyzed the $P(r, 334-360)$ data measured by DEER using Tau187 labeled across sites 344 & 360. Again, the heparin fibrils (green) yielded a distance distribution, which is distinct from the CBD (pink) and PSP lysate-seeded fibrils (blue) (Fig. 4b). The experimental $P(r, 334-360)$ of CBD lysate-seeded fibrils (pink solid line) contains a peak comprising the expected distance distribution (pink dotted line) centered around 2.5 nm. The $P(r, 334-360)$ of PSP lysate-seeded fibrils also has a dominant peak centered around 5-7 nm, which is closer to the expected distance of 7.5 nm. In contrast, the $P(r, 334-360)$ of the heparin fibrils significantly differs from the measured $P(r)$ of each of the two lysate-seeded fibrils, with no peaks present at distances above 6 nm. Again, the $P(r)$ shape is remarkably reproducible across biological triplicates (in terms of the seeded tau fibril material), all shown in Fig. S7, and is distinct between CBD and PSP lysate-seeded fibrils, despite the greater complexity and width of the experimentally observed $P(r)$ than commonly deemed interpretable.

The results for $P(r, 340-378)$, presented in Fig. 4c), show again a highly distinct $P(r)$ pattern for the heparin-induced fibril compared to the lysate-seeded tau fibril populations. However this time, the $P(r)$ between CBD or PSP lysate-seeded fibrils could not be distinguished. The major peak recorded from the CBD or PSP lysate-seeded fibrils is around 7-10 nm. This is slightly greater than the expected mean distance of 7.5 nm for the CBD fold, and much greater than the expected 5.5 nm for the PSP fold. Still, the distances contributing to the experimental $P(r)$ data from CBD and PSP lysate-seeded fibrils were significantly greater than those found in heparin fibrils. The measurements of $P(r, 340-378)$ have been intrinsically more challenging compared to $P(r, 351-373)$ and $P(r, 334-360)$ given that the expected distance range between sites 340 and 378 was the largest (5.5 to 8 nm) and is, therefore, close to the limitations of DEER with the given phase memory time, T_m , of 4 μ s using Tau187 fibrils prepared under the conditions of this study. Additionally, site 378 lies at the most terminal position of the structure, with respect to the expected CBD or PSP fibril core [19, 21], compared to all other spin-labeled sites tested here. The K18 tau expressed in the Tau4RD*LM-YFP cells also ends at residue 378, and the subsequent C-terminal residues present in both the CBD and PSP folds may be key to stabilizing the structures. It is, therefore, quite likely that the terminal segment around site 378 may not be fully folded into the CBD or PSP cell-passaged seeds used here, resulting in additional broadening and uncertainty in the $P(r)$ shape. Conventionally, the interpretation of $P(r, 340-378)$ data given the very broad features spanning distances exceeding 7 nm as found with CBD and PSP lysate-seeded fibrils is not viable. However, the remarkable reproducibility of $P(r)$ patterns between triplicates as shown in Fig. S8 demonstrates that the structural features, as seen through the dipolar coupling distributions between spin-labels at sites 340-378 are reproducible between the fibrils generated by each of the three methods.

When comparing the DEER-derived $P(r)$ of Tau187 in the monomer and heparin-induced fibril state across sites 351-373, 334-360, and 340-378 (shown in Fig. S4), it is clear that the protein region spanning sites 340-378 is part of semi-ordered fibril and certainly not simply an intrinsically disordered fuzzy coat, as the $P(r, 340-378)$ of heparin-induced fibril exhibited a single peak. This result is not necessarily obvious, given that sites 334, 351, 360, 373, and 378 have not been reported to be part of any heparin-induced fibril fold according to cryo-EM [25], further highlighting the ability of DEER to report on less homogeneous and more dynamic protein folds within fibrils. Each $P(r)$ of CBD or PSP lysate-seeded fibrils contain populations that feature greater distances between sites 351-373, 334-360, and 340-378, compared to heparin-induced fibrils, demonstrating that these sites are located at the outer core of a sub-population of tau fibrils, as designed by using the PDB structure of the CBD and PSP folds as our guide. These results, taken together, show that DEER can successfully be used to quantify differences in strain-specific tau misfolding. Using DEER, we discovered that the *in vitro* CBD and PSP lysate-seeded fibrils contain sub-populations of fibrils that adopt structural features that are consistent with the tau structures found in CBD and PSP patients by cryo-EM. These findings indicate that cell-passaged CBD and PSP tau can guide partial structural convergence of recombinant tau, suggesting that the cell-passaged seeds transmit their structural properties to naïve tau by templated misfolding. While these results validate the commonly assumed hypothesis of templated seeding, they are still surprising considering that the biosensor cell lines used in this study express K18 tau containing the segment 244-378 that does not encompass the entire tau segment that forms the PSP and CBD core. These results suggest that seeding with cell-passaged patient-derived tau populates multiple fibril structures. It is also possible that due to particle picking and class averaging in cryo-EM, the method can only resolve the dominant fibril sub-population, failing to capture the larger cloud of conformations that may exist in the human brain. Without these same limitations, our cell-based approach is able to propagate a greater ensemble of structures. Hence, the optimization of experimental conditions to achieve structural convergence to homogeneous tauopathy-specific fibrils predicates the availability of an experimental approach to measure the complete ensemble of the fibril population that guides such effort.

3 Discussion

In this study, we successfully used cell-passaged CBD and PSP patient samples to induce recombinant tau fibrillization without the addition of any cofactors or the use of sonication. Moreover, the resulting fibrils were able to reinfect the Tau4RD*LM-YFP cells (Fig. 3c & d). Using DEER-based distance measurements at sufficiently high-resolution and sub-nanometer levels, we found that the CBD and PSP lysate-seeded fibrils are morphologically distinct from one

another, as well as from heparin-induced tau fibrils (Fig. 4). Together, these results indicate that we can propagate and measure distinct fibril structures.

Our results are consistent with the predominant hypothesis that tau fibril propagation uses the prion mechanism of disease to self-template distinct conformations or strains. While cryo-EM has revealed a diverse array of tau fibril conformations [19–23, 23, 44], the ability to replicate these structures upon seeding has only recently been completed at high-resolution. At the time of submission of this paper, an exciting study was posted to BioRxiv by Tarutani *et al.* reporting the first cryo-EM structures of cell-passaged insoluble tau fibrils [49]. Complementing this exciting work, we show here that DEER can uniquely capture an ensemble of structures within a larger population, not just a homogeneous and dominant sub-population.

Previously, morphological and biochemical properties were used to demonstrate that distinct tau conformations exist [13, 14, 27, 27, 28, 33], and similar features between the seeded fibrils and the starting seed, or tau prion, have been used to determine the fidelity of tau templating [13, 14, 27–33, 35]. For example, Kaufman *et al.* [10] isolated and characterized 18 tau strains that originated from either recombinant protein, tauopathy mouse brain, or deceased human tauopathy patient samples. The isolated strains were categorized by multiple methods, including inclusion morphology, detergent solubility, seeding activity, proteolytic digestion, and toxicity. After inoculating transgenic mouse brains with the 18 strains, the unique patterns of neuropathological lesions induced by each strain were faithfully transmitted, indicating that the seeded fibrils in mice are similar to the starting material in the inocula. In a more recent study, Xu *et al.* [33] showed that AD patient samples may be used to template recombinant tau misfolding, resulting in fibrils that adopt the same conformation. While their analyses lacked conformation via cryo-EM, the conformation-dependent antibodies DMR7 and MC1 were able to bind to the AD-induced fibrils. In contrast, others have found that the AD seeded fibrils adopt conformations that are distinct from the starting material, as determined by unique protease digestion patterns and macroscopic morphology of induced fibrils [13, 50]. The current state of the literature shows that high-resolution tools are needed to investigate strain-specific templated misfolding of tau, and that studies, as presented here, will contribute to the critical ongoing debate on the molecular basis of tau prions and shape-selected fibril formation.

Using DEER, we detected partial distance features of seeded tau fibrils that are similar to the expected distances measured from the cryo-EM structures of CBD and PSP tau. These findings indicate that we achieved some convergence with these structures using seeding, even when using imperfect cellular seed material. One might view these results only as partial success given that the fibril structures did not converge to a single structure resembling the CBD or PSP fold. While achieving complete convergence to disease fold is an ultimate goal, the data presented here highlight a critical and unique strength of DEER, that it is capable of capturing the entire population of tau

folds within the formed fibrils. No other experimental technique could reveal that tauopathy seeds derived from cell lysates do, on the one hand, generate the originally targeted disease fold, but on the other hand, also report that many other fibril structures coexist with the disease fold. The ability to capture the entire conformational population is powerful because this tool offers us the opportunity to learn what dominant and relevant factors are needed to achieve conformation selection and convergence.

Importantly, there are a few factors that may account for this partial convergence, rather than complete replication of fibril structure. First, the cell-passaged seeds were generated in cells expressing K18 (or 4RD) tau which lacks the N- and C-termini. Although the K18 tau in cells may be templated by human materials, residues outside of the MTBR (such as the C-terminal region after residue 378) may contribute to tau folding, strain propagation, and/or structural stabilization. As a result, the CBD and PSP folds may only partially form in cells. This is potentially reflected in the indistinguishable P(r , 340-378) data measured from the CBD and PSP lysate-seeded fibrils. Moreover, despite the use of an 18-amino acid flexible linker, the fusion of K18 tau to a fluorescent protein may induce steric hindrance that inhibits or alters tau aggregation, as reported recently [51]. However, K18 tau is still important because it is so far the most commonly used construct in cellular seeding assays [11, 24, 52–62]. We, therefore, need to know how to interpret the wealth of critical data previously reported, no matter what the ultimate verdict is (e.g., whether the 4RD seeds do or do not faithfully template disease folds). Furthermore, truncated tau remains biologically relevant because fragments of tau have been identified in disease AD patient brain samples [61] and in patient cerebrospinal fluid [63–65]. Moreover, the linker sequencing connected tau and GFP in the studies by Kaniyappan *et al* (GAPGSAGSAAGSG) is not the same linker sequence used in the cell model used here (EFCSRRYRGPGIHRSP_TA). It is unclear how differences in the length or flexibility of these two linker sequences may contribute to our findings, and therefore how translatable the work by Kaniyappan *et al* is to the model system used here. In light of this discrepancy in the literature, others have shown that the presence of a GFP tag on α -synuclein does not interfere with *in vitro* fibrillization [66]. Therefore, it remains an open question whether the cell-passaged seeds are disrupted by the YFP tag and the truncation.

Second, the cell-free seeding conditions used in this study may not favor the propagation of specific disease-relevant strains, resulting in the formation of multiple conformers. For example, no disease-relevant PTMs are present on the recombinant tau used here. Furthermore, the exact makeup of the solution conditions, including molecular chaperones, crowders, cofactors, and even salt type and concentrations likely play major roles in dictating the tauopathy folding pathway to pathological fibrils. In fact, a recent study using cryo-EM [45] showed that simply changing salt types and salt concentration in the seeding buffer dramatically alters the shape of the resulting tau fibrils. By systematically and empirically changing the buffer conditions, the authors successfully

generated recombinant tau fibrils identical to the conformations reported for AD and CTE tau. Therefore, further optimization of the seeding conditions may be needed. Most importantly, our approach offers the opportunity to understand the underlying mechanism(s) for shape selection in tau seeding.

We need to consider two important factors when interpreting Cryo-EM structures of tau fibrils. The cryo-EM structures are generated using samples from deceased patients and therefore represent the end stage of the disease. It is possible that the process of tau misfolding in a living patient is more dynamic. Hence, the heterogeneous nature of the tau fibril population reflected in our data set captured from fibril samples 24 h after seeding may even be biologically relevant. Additionally, the class averaging required to resolve these structures is likely to select the most abundant conformations among a population of fibrils. However, as has been shown for the prion protein, there may be a mixture, or cloud, of conformations present in patients with CBD and PSP. If this is the case, it is less likely that cryo-EM studies will resolve the less abundant tau species, which we may be detectable by DEER, demonstrating the need for complementary structural biology tools.

4 Conclusion

We demonstrate that the recombinant tau fibrils induced by CBD and PSP cell-passaged seeds are structurally distinct from heparin-induced fibrils and that a sub-population of the lysate-seeded fibrils resemble the CBD and PSP fibrils isolated from human patient samples. These findings validate the application of DEER to investigate the self-templating process during tau propagation at high-resolution. Moreover, these data will also be important for guiding the development of strain-specific positron emission tomography (PET) ligands [67]. Given the conformational diversity of tau fibrils across tauopathy patients, it is unsurprising that previously developed PET probes bind some conformations with a much higher affinity than others (such as the APN-1607 binding to tau inclusions from AD and PSP patients)[68, 69]. In order to improve the diagnosis of tauopathies in living patients, additional PET ligands specific to each conformation are needed.

5 Methods

5.1 Human patient samples

The CBD patient sample used was provided by the NIH NeuroBioBank. This sample was from a 65-year-old male patient. The PSP patient sample used was provided by the Massachusetts Alzheimer’s Disease Research Center. This sample was from a 70-year-old female patient. Fresh-frozen human tissue was used to create a 10% (wt/vol) homogenate using calcium- and magnesium-free 1X Dulbecco’s phosphate-buffered saline (DPBS) using an Omni Tissue Homogenizer (Omni International).

5.2 Cell line development

The human tau DNA sequence encoding residues 244-378 with the P301L and V337M mutations (based on the longest tau isoform, 2N4R) fused to enhanced yellow fluorescent protein by an 18 amino acid flexible linker (EFC-SRRYRGPGIHRSP_{TA}) was synthesized and cloned into the pcDNA3.1(+) expression vector by GenScript. The Tau4RD*LM-YFP sequence was then subcloned into the pIRESpuro3 vector (Takara) using EcoRV (5') and NotI (3'). The same protocol was used to construct a plasmid containing the repeat domain of 3R tau (residues 244-274,306-378) containing the L226V and V337M mutations. Gene sequence and insertion were confirmed by Sanger sequencing before subsequent use.

HEK293T cells (ATCC) were cultured in Dulbecco's modified Eagle's medium (DMEM; Corning) supplemented with 10% fetal bovine serum (FBS), 100 μ g/mL penicillin, and 100 μ g/mL streptomycin (ThermoFisher), referred to hereafter as complete media. Cultures were maintained in a humidified atmosphere of 5% CO₂ at 37 °C. Cells were plated at a density of 5.7 X 10⁵ cells per well in a 6-well plate overnight in complete media before adding 1 μ g of plasmid DNA incubated with 3.5 μ L Lipofectamine 2000 (ThermoFisher) for 20 min. Stable cells were selected in complete media containing 1 μ g/mL puromycin (ThermoFisher) for 48 h before generating monoclonal lines by limiting dilution of polyclonal cells in 384-well plates. The resulting monoclonal lines were frozen in liquid nitrogen. Lysates from the lines were collected in 1X radioimmunoprecipitation assay (RIPA) buffer containing 50 mM Tris-HCl, pH 7.5 (ThermoFisher), 150 mM NaCl (Sigma), 5 mM EDTA (ThermoFisher), 1% nonidet P-40 (ThermoFisher), 0.5% deoxycholate (ThermoFisher), and 0.1% sodium dodecyl sulfate (SDS; ThermoFisher). Cell lysates in RIPA buffer were frozen, thawed, and clarified using two low-speed spins (500 x g for 5 min followed by 1,000 x g for 5 min). Total protein was measured in the supernatants via bicinchoninic acid (BCA) assay (Pierce). To compare the expression of tau-YFP across the clones, a total of 10 μ g total protein was prepared in 1X NuPAGE LDS loading buffer and boiled for 10 min. Samples were loaded onto a 10% Bis-Tris gel (ThermoFisher) and SDS-PAGE was performed using the MES buffer system. Protein was transferred to a polyvinylidene fluoride (PVDF) membrane. The membrane was blocked in blocking buffer [5% (wt/vol) nonfat milk in 1X Tris-buffered saline containing 0.05% (vol/vol) Tween 20 (TBST)] for 30 min at room temperature. Blots were incubated with primary antibody for GFP (1:10,000; Abcam) in block buffer overnight at 4 °C. Membranes were washed three times with 1X TBST before incubating with horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (1:10,000; Abcam) diluted in blocking buffer for 1 h at 4 °C. After washing blots three times in 1X TBST, membranes were developed using the enhanced chemiluminescent detection system (Pierce) for exposure to X-ray film. This same protocol was used to evaluate tau-YFP expression in uninfected vs infected cells.

To generate cells that stably propagate tau prions, fresh frozen human brain tissue samples from one CBD and one PSP patient sample were used. Tau prions were isolated from the samples using sodium phosphotungstic acid (NaPTA; Sigma) as described [11]. Isolated protein pellets were stored at 4 °C. Tau4RD*LM-YFP cells were infected with tau prions isolated from the CBD or PSP patient samples as described below. Monoclonal subclones stably propagating tau prions were generated by isolated Tau4RD*LM-YFP cells by limiting dilution of a polyclonal cell population in 384-well plates. Clones were selected by the presence of YFP-positive aggregates in >95% of cells in the culture. Resulting monoclonal lines were frozen in liquid nitrogen.

5.3 Cellular tau prion bioassay

Tau4RD*LM-YFP cells were plated in 384-well plates with black polystyrene walls (Greiner) with 0.012 μ g Hoechst 33342 (ThermoFisher) at a density of 4,000 cells/well. Tau3RD*VM-YFP cells were plated using the same conditions at a density of 2,750 cells/well. Cells were incubated at 37 °C for 2 to 4 h to allow adherence to the plate. To infect Tau4RD*LM-YFP cells, PTA-precipitated patient samples diluted 1:5 in 1X DPBS or 0.05 μ M fibrils in 1X DPBS were incubated with Lipofectamine 2000 2% final volume; ThermoFisher) for 1.5 h at room temperature. OptiMEM (78% final volume; ThermoFisher) was added before each sample was plated in six replicate wells. To infect Tau3RD*LM-YFP cells, PTA-precipitated patient samples diluted 1:20 in 1X DPBS or 0.05 μ M fibrils in 1X DPBS were incubated with Lipofectamine 2000 1% final volume; ThermoFisher) for 1.5 h at room temperature. OptiMEM (79% final volume; ThermoFisher) was added before each sample was plated in six replicate wells. Plates were then incubated at 37 °C in a humidified atmosphere of 5% (vol/vol) CO₂ for 4 days before imaging on the Molecular Devices XLS. Images of both the DAPI and YFP channels were collected from five different regions in each well. The images were analyzed using an algorithm built in Custom Module Editor (Molecular Devices) to identify intracellular aggregates only in living cells. Data reported as fluorescence/cell X 10⁶ arbitrary units (A.U.).

5.4 Tau187 and 0N4R expression and purification

N-terminal truncated, microtubule-binding domain containing Tau187 (residues 255-441 with a His-tag at the N-terminus) and 0N4R were used for *in vitro* studies. Mutated variants of Tau187 were prepared using site-direct mutagenesis: cysteine-less (cysless) Tau187 P301L/Q351C/T373C contains C291S, C322S, Q351C and T373C; cysless Tau187 P301L/G334C/I360C contains C291S, C322S, G334C and I360C; cysless Tau187 P301L/K340/F378C contains C291S, C322S, K340 and F378C. Cysless Tau187 P301L and cysless 0N4R P301L constructs were made with C291S and C322S mutations.

The cloning, expression, and purification of Tau187 have been previously described [70]. Shortly, the gene encoding desired Tau187 tau or 0N4R tau

was cloned into a pET-28a vector and was transfected into E. coli. BL21 (DE3) competent cells (Novagen). E. coli BL21 (DE3) cells were cultured from frozen glycerol stock or from plates overnight in 10 mL luria broth (LB) which was used to inoculate 1 L of fresh LB. Culturing and inoculation were performed at 37 °C with shaking of 200 rpm. At OD 600 of 0.6-0.8, Tau187 variant expression was induced by incubation with 1 mM isopropylβ-D-thiogalactoside (Sigma Aldrich) for 2-3 h. Cells were harvested by centrifugation for 10 min at 5000 × g (Beckman J-10; Beckman Instruments, Inc.), and the pellets were stored at -20 °C until further use. Cell pellets were resuspended in lysis buffer (Tris-HCl pH 7.4, 100 mM NaCl, 0.5 mM DTT, 0.1 mM EDTA, 1mM PMSF) with 1 Pierce protease inhibitor tablet (Thermo Fisher). Lysis was initiated by the addition of lysozyme (2 mg/ml), DNase (20 µg/ml), and MgCl₂ (10 mM) and incubated for 30 min on ice. Lysate was then heated to 65 °C for 13 min, cooled on ice for 20 min and then centrifuged to remove the precipitant. The supernatant was loaded onto a Ni-NTA agarose column pre-equilibrated with wash buffer A (20 mM sodium phosphate pH 7.0, 500 mM NaCl, 10 mM imidazole, 100 µM EDTA). The column was then washed with 20 ml of buffer A, 15 ml buffer B (20 mM sodium phosphate pH 7.0, 1 M NaCl, 20 mM imidazole, 0.5 mM DTT, 100 µM EDTA). Purified Tau187 was eluted with buffer C (20 mM sodium phosphate pH 7.0, 0.5 mM DTT, 100 mM NaCl) supplemented with varying amounts of imidazole increasing from 100 mM to 300 mM. The protein was then concentrated via Amicon Ultra-15 centrifugal filters (MWCO 10 kDa; Millipore Sigma) and the buffer was exchanged into final buffer (20 mM ammonium acetate buffer at pH 7.0, or 20mM HEPES at pH 7.4) by PD-10 desalting column (GE Healthcare). To further purify the protein, size exclusion chromatography was conducted by injecting 2-5 mL sample onto HiLoad 16/600 Superdex 200 Column (GE Healthcare Life Sciences) connected to a BioRad NGC Quest 10 FPLC system, and 1.5 mL fractions were collected with a BioFrac fraction collector (BioRad). Prior to sample injection, the column was washed by 130 mL degassed Milli-Q water at a flow rate of 0.8 mL/min and equilibrated with 160 mL degassed working buffer (20 mM ammonium acetate buffer at pH 7.0, or 20mM HEPES at pH 7.4) at 0.8 mL/min. Samples were eluted from the column with 150 mL working buffer at 0.6 mL/min after sample injection. Fractions of each elution peaks were collected right after elution. Elution peak assignment was done by comparing with the elution profile of purified Tau187 monomers. Fractions corresponding to monomer were concentrated using Amicon Ultra-4 centrifugal filters (MWCO 10 kDa; Millipore Sigma). The final protein concentration of Tau187 was determined by UV-Vis absorption at 274 nm using an extinction coefficient of 2.8 $cm^{-1}mM^{-1}$ calculated from absorption of Tyrosine. The final protein concentration of 0N4R was determined by UV-Vis absorption at 274 nm using an extinction coefficient of 7.4 $cm^{-1}mM^{-1}$ calculated from absorption of Tyrosine.

5.5 Protein spin-labeling

Protein was spin-labeled using MTSL ((1-Acetoxy-2,2,5,5-tetramethyl- δ -3-pyrroline-3-methyl) Methanethiosulfonate) purchased from Toronto Research Chemicals. Prior to labeling, samples were treated with 5 mM DTT, which was removed using a PD-10 desalting column. Then, 10 $\times$ to 15 $\times$ molar excess MTSL to free cysteine was incubated with the protein at 4 °C overnight. Excess MTSL was removed using a PD-10 desalting column. Labeling efficiency, defined as the molar ratio of tethered spin-labels over the cysteines, was measured to be 50-60% for double-cysteine mutants.

5.6 Heparin-induced tau aggregation

Cell-free tau aggregation was carried out in the working buffer (20mM HEPES at pH 7.4) at 37 °C. 20 μ M ThT dye was added into 50 μ M Tau187 in Corning™ 384-Well Solid Black Polystyrene Microplates (Thermo Fisher Scientific). Then, heparin was mixed in the samples at the mole ratio of 4:1 (Tau187:heparin) to induce aggregation. ThT fluorescence was monitored by Bio-Tek Synergy 2 microplate reader (excitation 440/30, emission 485/20, number of flash 16, gain 50) over a period of 24h at 37 °C. One data point was taken every 3 minutes. Measurements were done in triplicate. The figures showed the average and standard deviations.

5.7 Cell-free seeding assay

5% to 15% (protein mass percentage) of CBD and PSP cell-passaged seeds were incubated with 50 μ M cysless P301 Tau187 in 20 mM HEPES buffer to make seeded fibrils. 20 μ M ThT was added to the mixture and the fluorescence was monitored by Bio-Tek Synergy 2 microplate reader using the same setting and as heparin-induced aggregation. One data point was taken every 3 minutes. Measurements were done in triplicate. The figures showed the average and standard deviations.

5.8 TEM

TEM grids were plasma cleaned (for 20s at 60W power) with the shiny side up and used within 1 hour for preparation. 1 drop (5ul) of fibril sample and two drops (5ul each) of 2 percent UA (Uranyl Acetate) were placed on a parafilm for each grid. The shiny side was then floated on the fibril sample for 1 minute and was blotted once with Wattman filter paper. The grid was then touched with one drop of UA and blotted immediately. It was then placed on the second UA drop for 1 minute and then blotted well. The grids were dried for 2-3 hours, before imaging. Images were collected on a Talos F200X (Thermo Fisher Scientific) operating at 200 kV and equipped with a Ceta II CMOS 4k x 4k camera for high-quality HRTEM imaging.

5.9 Double Electron Electron Resonance (DEER)

Double-cysteine Tau187 was expressed and spin-labeled as doubly-labeled Tau187 that contains two spin-labels in order to probe distances between two target residues (residues 351 and 373, residues 334 and 360, and residues 340 and 378). Cysless Tau187 was expressed and purified to avoid disulfide bonding. doubly-labeled Tau187 and cysless Tau187 were stored in 20 mM HEPES in H₂O. A 1:10 molar ratio doubly-labeled Tau187:cysless Tau187 sample of 57 μ M doubly-labeled Tau187 and 570 μ M cysless Tu187 was incubated with 157 μ M heparin at 37 °C 24 h to prepare heparin fibrils. As for CBD and PSP lysate-seeded fibrils, a 1:10 molar ratio doubly-labeled Tau187:cysless Tau187 sample of 200 μ M doubly-labeled Tau187 and 200 μ M cysless was incubated with 15% (mass) CBD or PSP cell-passaged seeds at 37 °C for 24 h to prepare seeded fibrils. 50 μ L of fibrils were then dialyzed to D₂O-based buffer ((20mM HEPES at pH 7.4) at room temperature for 6 h using Pur-A-Lyzer™ Mini Dialysis Kit (Mini 25000, MWCO 25 kDa). 35 μ L samples were then mixed with 15 μ L D8-glycerol (30% volume) before transferring to a quartz tube (3 mm o.d., 2 mm i.d.) and frozen using liquid nitrogen.

The DEER experiments were performed with a pulsed Q-band Bruker E580 Eleksys spectrometer, equipped with a Bruker QT-II resonator and a 300 W TWT amplifier with an output power of 20 mW for the recorded data (Applied Systems Engineering, Model 177Ka). The temperature of the cavity was maintained at 65 K using a Bruker/ColdEdge FlexLine Cryostat (Model ER 4118HV-CF100). The bridge is equipped with an Arbitrary Wave Generator to create shaped pulses for increased sensitivity. The following DEER pulse sequence was used: $\pi_{obs}/2 - \tau_1 - \pi_{obs} - (t - \pi_{pump}) - (\tau_2 - t) - \pi_{obs} - \tau_2 - \text{echo}$. Experiment dipolar signal, $V(t)$, was recorded as the integral of the refocused echo as a function of time delay, t . Rectangular observe pulses were used with lengths set to $\pi_{obs}/2 = 10\text{--}12$ ns and $\pi_{obs} = 20\text{--}24$ ns. A chirp π pump pulse was applied with a length of 100 ns and a frequency width of 60 MHz. The observed frequency was 90 MHz higher than the center of the pump frequency range. τ_1 was set to 180 ns for heparin samples and set to the first harmonic in the two-pulse deuterium ESEEM trace (126-128 ns). τ_2 was set according to the SNR profile of the dipolar signal. The data was acquired with Δt of 16 ns, 16-step phase cycling, and signal averaged until desirable SNR was obtained.

5.10 DEER data analysis

All DEER time traces were transformed into distance distributions using DeerLab software package for Python. The time traces were phase corrected and truncated by 300 ns to remove possible "2+1"-artifact. One-step analysis was done using the DeerLab fit function with the following models: ex-4deer model with t_1 , t_2 , and pulselength set to experiment parameters, bg-strexp model with the stretch parameter freed to 1.5 (base on previous measurements of dimensions of singularly labeled samples), and dipolarmodel using Tikhonov regularization. The uncertainty analysis was done using bootstrapping method

with 100 samples. The time domain fitting results are presented both as fitting to the primary data and the background-corrected data, and the distance distribution fits are presented with 95% confidence intervals.

5.11 Statistical analysis

Cell infection data are presented as mean $\pm$ SD. The value represents the averages of five images collected from each well of a 384-well plate. Technical replicates for each sample were averaged across six wells. Statistical comparisons between control and diseased patient samples, and between monomer and fibrils, were performed using a one-way ANOVA with a Dunnett post-hoc analysis. Statistical significance for all tests was determined with a P value < 0.05 .

6 Supplementary information

SI is attached as PDF.

7 Acknowledgments

The authors thank the DeerLab developers [48] for making an enhanced DEER analysis software available and Dr. Madhur Srivastava for continued discussion and support for DEER data analysis. Human tissue was obtained from the NIH NeuroBioBank and the Massachusetts Alzheimer’s Disease Research Center. We acknowledge support by the Tau Consortium (www.tauconsortium.org) from the Rainwater Charitable Foundation for the study of tau seeding (S.H. and A.W.).

The W. M. Keck Foundation (www.wmkeck.org) is acknowledged for ongoing method developments for the tau shape propagation study (S.H.). The National Institute of Health (NIH) under grant number R01AG05605 is acknowledged for supporting the aggregation mechanism study of key tau fragments (S.H., K.Z., V.V). The NIH MIRA under grant number R35GM136411 supported the basic science development of DEER methods and analysis used in this study (K.T). This work was also supported by a Venture Grant (668-2020-06) from the CurePSP Foundation and the University of Massachusetts Amherst (A.L.W.).

Editorial Policies for:

Springer journals and proceedings:

<https://www.springer.com/gp/editorial-policies>

Nature Portfolio journals:

<https://www.nature.com/nature-research/editorial-policies>

Scientific Reports:

<https://www.nature.com/srep/journal-policies/editorial-policies>

BMC journals:

<https://www.biomedcentral.com/getpublished/editorial-policies>

References

- [1] Nelson, P.T., Alafuzoff, I., Bigio, E.H., Bouras, C., Braak, H., Cairns, N.J., Castellani, R.J., Crain, B.J., Davies, P., Del Tredici, K., Duyckaerts, C., Frosch, M.P., Haroutunian, V., Hof, P.R., Hulette, C.M., Hyman, B.T., Iwatsubo, T., Jellinger, K.A., Jicha, G.A., Kövari, E., Kukull, W.A., Leverenz, J.B., Love, S., Mackenzie, I.R., Mann, D.M., Masliah, E., McKee, A.C., Montine, T.J., Morris, J.C., Schneider, J.A., Sonnen, J.A., Thal, D.R., Trojanowski, J.Q., Troncoso, J.C., Wisniewski, T., Woltjer, R.L., Beach, T.G.: Correlation of alzheimer disease neuropathologic changes with cognitive status: a review of the literature. *J. Neuropathol. Exp. Neurol.* **71**(5), 362–381 (2012)
- [2] Arriagada, P.V., Marzloff, K., Hyman, B.T.: Distribution of alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in alzheimer’s disease. *Neurology* **42**(9), 1681–1688 (1992)
- [3] Götz, J., Halliday, G., Nisbet, R.M.: Molecular pathogenesis of the tauopathies. *Annu. Rev. Pathol.* **14**, 239–261 (2019)
- [4] Goedert, M., Eisenberg, D.S., Crowther, R.A.: Propagation of tau aggregates and neurodegeneration. *Annual Review of Neuroscience*, Vol 40 **40**, 189–210 (2017)
- [5] Goedert, M.: Tau filaments in neurodegenerative diseases. *FEBS Lett.* **592**(14), 2383–2391 (2018)
- [6] Walker, L.C., Jucker, M.: Neurodegenerative diseases: Expanding the prion concept. *Annual Review of Neuroscience*, Vol 38 **38**, 87–103 (2015)
- [7] Clavaguera, F., Akatsu, H., Fraser, G., Crowther, R.A., Frank, S., Hench, J., Probst, A., Winkler, D.T., Reichwald, J., Staufenbiel, M., Ghetti, B., Goedert, M., Tolnay, M.: Brain homogenates from human tauopathies

- induce tau inclusions in mouse brain. *Proc. Natl. Acad. Sci. U. S. A.* **110**(23), 9535–9540 (2013)
- [8] Guo, J.L., Lee, V.M.Y.: Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. *Nat. Med.* **20**(2), 130–138 (2014)
- [9] Sanders, D.W., Kaufman, S.K., DeVos, S.L., Sharma, A.M., Mirbaha, H., Li, A., Barker, S.J., Foley, A.C., Thorpe, J.R., Serpell, L.C., Miller, T.M., Grinberg, L.T., Seeley, W.W., Diamond, M.I.: Distinct tau prion strains propagate in cells and mice and define different tauopathies. *Neuron* **82**(6), 1271–1288 (2014)
- [10] Kaufman, S.K., Sanders, D.W., Thomas, T.L., Ruchinskas, A.J., Vaquer-Alicea, J., Sharma, A.M., Miller, T.M., Diamond, M.I.: Tau prion strains dictate patterns of cell pathology, progression rate, and regional vulnerability in vivo. *Neuron* **92**(4), 796–812 (2016)
- [11] Woerman, A.L., Aoyagi, A., Patel, S., Kazmi, S.A., Lobach, I., Grinberg, L.T., Mckee, A.C., Seeley, W.W., Olson, S.H., Prusiner, S.B.: Tau prions from alzheimer’s disease and chronic traumatic encephalopathy patients propagate in cultured cells. *Proc. Natl. Acad. Sci. U. S. A.* **113**(50), 8187–8196 (2016)
- [12] Narasimhan, S., Guo, J.L., Changolkar, L., Stieber, A., McBride, J.D., Silva, L.V., He, Z., Zhang, B., Gathagan, R.J., Trojanowski, J.Q., Lee, V.M.Y.: Pathological tau strains from human brains recapitulate the diversity of tauopathies in nontransgenic mouse brain. *J. Neurosci.* **37**(47), 11406–11423 (2017)
- [13] Nizynski, B., Nieznanska, H., Dec, R., Boyko, S., Dzwolak, W., Nieznanski, K.: Amyloidogenic cross-seeding of tau protein: Transient emergence of structural variants of fibrils. *PLoS One* **13**(7), 0201182 (2018)
- [14] Mirbaha, H., Chen, D., Morazova, O.A., Ruff, K.M., Sharma, A.M., Liu, X., Goodarzi, M., Pappu, R.V., Colby, D.W., Mirzaei, H., Joachimiak, L.A., Diamond, M.I.: Inert and seed-competent tau monomers suggest structural origins of aggregation. *Elife* **7** (2018)
- [15] Skachokova, Z., Martinisi, A., Flach, M., Sprenger, F., Naegelin, Y., Steiner-Monard, V., Sollberger, M., Monsch, A.U., Goedert, M., Tolnay, M., Winkler, D.T.: Cerebrospinal fluid from alzheimer’s disease patients promotes tau aggregation in transgenic mice. *Acta Neuropathol Commun* **7**(1), 72 (2019)
- [16] He, Z., McBride, J.D., Xu, H., Changolkar, L., Kim, S.-J., Zhang, B., Narasimhan, S., Gibbons, G.S., Guo, J.L., Kozak, M., Schellenberg, G.D., Trojanowski, J.Q., Lee, V.M.-Y.: Transmission of tauopathy strains is

- independent of their isoform composition. *Nat. Commun.* **11**(1), 7 (2020)
- [17] Fitzpatrick, A.W.P., Falcon, B., He, S., Murzin, A.G., Murshudov, G., Garringer, H.J., Crowther, R.A., Ghetti, B., Goedert, M., Scheres, S.H.W.: Cryo-EM structures of tau filaments from alzheimer’s disease. *Nature* **547**(7662), 185–190 (2017)
 - [18] Falcon, B., Zhang, W., Schweighauser, M., Murzin, A.G., Vidal, R., Garringer, H.J., Ghetti, B., Scheres, S.H.W., Goedert, M.: Tau filaments from multiple cases of sporadic and inherited alzheimer’s disease adopt a common fold. *Acta Neuropathol.* **136**(5), 699–708 (2018)
 - [19] Zhang, W., Tarutani, A., Newell, K.L., Murzin, A.G., Matsubara, T., Falcon, B., Vidal, R., Garringer, H.J., Shi, Y., Ikeuchi, T., Murayama, S., Ghetti, B., Hasegawa, M., Goedert, M., Scheres, S.H.W.: Novel tau filament fold in corticobasal degeneration. *Nature* (2020)
 - [20] Arakhamia, T., Lee, C.E., Carlomagno, Y., Duong, D.M., Kunding, S.R., Wang, K., Williams, D., DeTure, M., Dickson, D.W., Cook, C.N., Seyfried, N.T., Petrucelli, L., Fitzpatrick, A.W.P.: Posttranslational modifications mediate the structural diversity of tauopathy strains. *Cell* **180**(4), 633–644 (2020)
 - [21] Falcon, B., Zivanov, J., Zhang, W., Murzin, A.G., Garringer, H.J., Vidal, R., Crowther, R.A., Newell, K.L., Ghetti, B., Goedert, M., Scheres, S.H.W.: Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. *Nature* **568**(7752), 420–423 (2019)
 - [22] Xiang, X., Arakhamia, T., Carlomagno, Y., Dhingra, S., Thierry, M., DeTure, M., Cook, C.N., Dickson, D.W., Petrucelli, L., Fitzpatrick, A.W.P.: Role of molecular polymorphism in defining tau filament structures in neurodegenerative diseases (2021)
 - [23] Shi, Y., Zhang, W., Yang, Y., Murzin, A.G., Falcon, B., Kotecha, A., van Beers, M., Tarutani, A., Kametani, F., Garringer, H.J., Vidal, R., Hallinan, G.I., Lashley, T., Saito, Y., Murayama, S., Yoshida, M., Tanaka, H., Kakita, A., Ikeuchi, T., Robinson, A.C., Mann, D.M.A., Kovacs, G.G., Revesz, T., Ghetti, B., Hasegawa, M., Goedert, M., Scheres, S.H.W.: Structure-based classification of tauopathies. *Nature* **598**(7880), 359–363 (2021)
 - [24] Mirbaha, H., Holmes, B.B., Sanders, D.W., Bieschke, J., Diamond, M.I.: Tau trimers are the minimal propagation unit spontaneously internalized to seed intracellular aggregation. *J. Biol. Chem.* **290**(24), 14893–14903 (2015)
 - [25] Zhang, W., Falcon, B., Murzin, A.G., Fan, J., Crowther, R.A., Goedert,

- M., Scheres, S.H.: Heparin-induced tau filaments are polymorphic and differ from those in alzheimer's and pick's diseases. *Elife* **8**, 43584 (2019)
- [26] Fichou, Y., Vigers, M., Goring, A.K., Eschmann, N.A., Han, S.I.: Heparin-induced tau filaments are structurally heterogeneous and differ from alzheimer's disease filaments. *Chem. Commun.* **54**(36), 4573–4576 (2018)
- [27] Frost, B., Ollesch, J., Wille, H., Diamond, M.I.: Conformational diversity of wild-type tau fibrils specified by templated conformation change. *J. Biol. Chem.* **284**(6), 3546–3551 (2009)
- [28] Morozova, O.A., March, Z.M., Robinson, A.S., Colby, D.W.: Conformational features of tau fibrils from alzheimer's disease brain are faithfully propagated by unmodified recombinant protein. *Biochemistry* **52**(40), 6960–6967 (2013)
- [29] Meyer, V., Dinkel, P.D., Rickman Hager, E., Margittai, M.: Amplification of tau fibrils from minute quantities of seeds. *Biochemistry* **53**(36), 5804–5809 (2014)
- [30] Weismiller, H.A., Murphy, R., Wei, G., Ma, B., Nussinov, R., Margittai, M.: Structural disorder in four-repeat tau fibrils reveals a new mechanism for barriers to cross-seeding of tau isoforms. *J. Biol. Chem.* **293**(45), 17336–17348 (2018)
- [31] Ghag, G., Bhatt, N., Cantu, D.V., Guerrero-Munoz, M.J., Ellsworth, A., Sengupta, U., Kaye, R.: Soluble tau aggregates, not large fibrils, are the toxic species that display seeding and cross-seeding behavior: Generation of tau aggregates via sonication. *Protein Sci.* **27**(11), 1901–1909 (2018)
- [32] Kraus, A., Saijo, E., Metrick, M.A. 2nd, Newell, K., Sigurdson, C.J., Zanusso, G., Ghetti, B., Caughey, B.: Seeding selectivity and ultrasensitive detection of tau aggregate conformers of alzheimer disease. *Acta Neuropathol.* **137**(4), 585–598 (2019)
- [33] Xu, H., O'Reilly, M., Gibbons, G.S., Changolkar, L., McBride, J.D., Riddle, D.M., Zhang, B., Stieber, A., Nirschl, J., Kim, S.-J., Hoxha, K.-H., Brunden, K.R., Schellenberg, G.D., Trojanowski, J.Q., Lee, V.M.-Y.: In vitro amplification of pathogenic tau conserves disease-specific bioactive characteristics. *Acta Neuropathol.* **141**(2), 193–215 (2021)
- [34] Eschmann, N.A., Georgieva, E.R., Ganguly, P., Borbat, P.P., Rappaport, M.D., Akdogan, Y., Freed, J.H., Shea, J.E., Han, S.: Signature of an aggregation-prone conformation of tau. *Sci. Rep.* **7** (2017)
- [35] Fichou, Y., Lin, Y., Rauch, J.N., Vigers, M., Zeng, Z., Srivastava, M., Keller, T.J., Freed, J.H., Kosik, K.S., Han, S.: Cofactors are essential

- constituents of stable and seeding-active tau fibrils. *Proc. Natl. Acad. Sci. U. S. A.* **115**(52), 13234–13239 (2018)
- [36] Stelzl, L.S., Fowler, P.W., Sansom, M.S.P., Beckstein, O.: Flexible gates generate occluded intermediates in the transport cycle of LacY. *J. Mol. Biol.* **426**(3), 735–751 (2014)
- [37] Woerman, A.L., Stöhr, J., Aoyagi, A., Rampersaud, R., Krejcirova, Z., Watts, J.C., Ohyama, T., Patel, S., Widjaja, K., Oehler, A., Sanders, D.W., Diamond, M.I., Seeley, W.W., Middleton, L.T., Gentleman, S.M., Mordes, D.A., Südhof, T.C., Giles, K., Prusiner, S.B.: Propagation of prions causing synucleinopathies in cultured cells. *Proc. Natl. Acad. Sci. U. S. A.* **112**(35), 4949–58 (2015)
- [38] Safar, J., Wille, H., Itri, V., Groth, D., Serban, H., Torchia, M., Cohen, F.E., Prusiner, S.B.: Eight prion strains have PrP(Sc) molecules with different conformations. *Nat. Med.* **4**(10), 1157–1165 (1998)
- [39] Barghorn, S., Mandelkow, E.: Toward a unified scheme for the aggregation of tau into alzheimer paired helical filaments. *Biochemistry* **41**(50), 14885–14896 (2002)
- [40] Nilsson, M.R.: Techniques to study amyloid fibril formation in vitro. *Methods* **34**(1), 151–160 (2004)
- [41] Ksiazek-Reding, H., Tracz, E., Yang, L.S., Dickson, D.W., Simon, M., Wall, J.S.: Ultrastructural instability of paired helical filaments from corticobasal degeneration as examined by scanning transmission electron microscopy. *Am. J. Pathol.* **149**(2), 639–651 (1996)
- [42] Murray, M.E., Kouri, N., Lin, W.-L., Jack, C.R. Jr, Dickson, D.W., Vemuri, P.: Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. *Alzheimers. Res. Ther.* **6**(1), 1 (2014)
- [43] Arima, K.: Ultrastructural characteristics of tau filaments in tauopathies: immuno-electron microscopic demonstration of tau filaments in tauopathies. *Neuropathology* **26**(5), 475–483 (2006)
- [44] Falcon, B., Zhang, W., Murzin, A.G., Murshudov, G., Garringer, H.J., Vidal, R., Crowther, R.A., Ghetti, B., Scheres, S.H.W., Goedert, M.: Structures of filaments from pick’s disease reveal a novel tau protein fold. *Nature* **561**(7721), 137–140 (2018)
- [45] Lövestam, S., Koh, F.A., van Knippenberg, B., Kotecha, A., Murzin, A.G., Goedert, M., Scheres, S.H.W.: Assembly of recombinant tau into filaments identical to those of alzheimer’s disease and chronic traumatic encephalopathy. *Elife* **11** (2022)

- [46] Hubbell, W.L., Altenbach, C.: Investigation of structure and dynamics in membrane proteins using site-directed spin labeling. *Curr. Opin. Struct. Biol.* **4**(4), 566–573 (1994)
- [47] Lerch, M.T., Yang, Z., Brooks, E.K., Hubbell, W.L.: Mapping protein conformational heterogeneity under pressure with site-directed spin labeling and double electron-electron resonance. *Proc. Natl. Acad. Sci. U. S. A.* **111**(13), 1201–10 (2014)
- [48] Fábregas Ibáñez, L., Jeschke, G., Stoll, S.: DeerLab: a comprehensive software package for analyzing dipolar electron paramagnetic resonance spectroscopy data. *Magn Reson (Gott)* **1**(2), 209–224 (2020)
- [49] Tarutani, A., Lövestam, S., Zhang, X., Kotecha, A., Robinson, A.C., Mann, D.M.A., Saito, Y., Murayama, S., Tomita, T., Goedert, M., Scheres, S.H.W., Hasegawa, M.: Cryo-EM structures of tau filaments from SH-SY5Y cells seeded with brain extracts from cases of Alzheimer’s disease and corticobasal degeneration (2023)
- [50] Nam, W.-H., Choi, Y.P.: In vitro generation of tau aggregates conformationally distinct from parent tau seeds of alzheimer’s brain. *Prion* **13**(1), 1–12 (2019)
- [51] Kaniyappan, S., Tepper, K., Biernat, J., Chandupatla, R.R., Hübschmann, S., Irsen, S., Bicher, S., Klatt, C., Mandelkow, E.-M., Mandelkow, E.: FRET-based tau seeding assay does not represent prion-like templated assembly of tau filaments. *Mol. Neurodegener.* **15**(1), 39 (2020)
- [52] Furman, J.L., Vaquer-Alicea, J., White, C.L. 3rd, Cairns, N.J., Nelson, P.T., Diamond, M.I.: Widespread tau seeding activity at early braak stages. *Acta Neuropathol.* **133**(1), 91–100 (2017)
- [53] Sanders, D.W., Kaufman, S.K., DeVos, S.L., Sharma, A.M., Mirbaha, H., Li, A., Barker, S.J., Foley, A.C., Thorpe, J.R., Serpell, L.C., Miller, T.M., Grinberg, L.T., Seeley, W.W., Diamond, M.I.: Distinct tau prion strains propagate in cells and mice and define different tauopathies. *Neuron* **82**(6), 1271–1288 (2014)
- [54] Hitt, B.D., Vaquer-Alicea, J., Manon, V.A., Beaver, J.D., Kashmer, O.M., Garcia, J.N., Diamond, M.I.: Ultrasensitive tau biosensor cells detect no seeding in alzheimer’s disease CSF. *Acta Neuropathol Commun* **9**(1), 99 (2021)
- [55] Rajasekhar, K., Mirbaha, H., Diamond, M.I., et al.: Site-specific hyperphosphorylation inhibits, rather than promotes, tau fibrillization, seeding capacity and its microtubule binding. *Angewandte* (2019)

- [56] Kfoury, N., Holmes, B.B., Jiang, H., Holtzman, D.M., Diamond, M.I.: Trans-cellular propagation of tau aggregation by fibrillar species. *J. Biol. Chem.* **287**(23), 19440–19451 (2012)
- [57] Frost, B., Jacks, R.L., Diamond, M.I.: Propagation of tau misfolding from the outside to the inside of a cell. *J. Biol. Chem.* **284**(19), 12845–12852 (2009)
- [58] Holmes, B.B., Furman, J.L., Mahan, T.E., Yamasaki, T.R., Mirbaha, H., Eades, W.C., Belaygorod, L., Cairns, N.J., Holtzman, D.M., Diamond, M.I.: Proteopathic tau seeding predicts tauopathy in vivo. *Proc. Natl. Acad. Sci. U. S. A.* **111**(41), 4376–4385 (2014)
- [59] DeVos, S.L., Corjuc, B.T., Oakley, D.H., Nobuhara, C.K., Bannon, R.N., Chase, A., Commins, C., Gonzalez, J.A., Dooley, P.M., Frosch, M.P., Hyman, B.T.: Synaptic tau seeding precedes tau pathology in human alzheimer’s disease brain. *Front. Neurosci.* **12**, 267 (2018)
- [60] Dujardin, S., Commins, C., Lathuiliere, A., Beerepoot, P., Fernandes, A.R., Kamath, T.V., De Los Santos, M.B., Klickstein, N., Corjuc, D.L., Corjuc, B.T., Dooley, P.M., Viode, A., Oakley, D.H., Moore, B.D., Mullin, K., Jean-Gilles, D., Clark, R., Atchison, K., Moore, R., Chibnik, L.B., Tanzi, R.E., Frosch, M.P., Serrano-Pozo, A., Elwood, F., Steen, J.A., Kennedy, M.E., Hyman, B.T.: Tau molecular diversity contributes to clinical heterogeneity in alzheimer’s disease. *Nat. Med.* **26**(8), 1256–1263 (2020)
- [61] Barini, E., Plotzky, G., Mordashova, Y., Hoppe, J., Rodriguez-Correa, E., Julier, S., LePrieult, F., Mairhofer, I., Mezler, M., Biesinger, S., Cik, M., Meinhardt, M.W., Ercan-Herbst, E., Ehrnhoefer, D.E., Striebinger, A., Bodie, K., Klein, C., Gasparini, L., Schlegel, K.: Tau in the brain interstitial fluid is fragmented and seeding-competent. *Neurobiol. Aging* **109**, 64–77 (2022)
- [62] Seidler, P.M., Boyer, D.R., Murray, K.A., Yang, T.P., Bentzel, M., Sawaya, M.R., Rosenberg, G., Cascio, D., Williams, C.K., Newell, K.L., Ghetti, B., DeTure, M.A., Dickson, D.W., Vinters, H.V., Eisenberg, D.S.: Structure-based inhibitors halt prion-like seeding by alzheimer’s disease- and tauopathy-derived brain tissue samples. *J. Biol. Chem.* **294**(44), 16451–16464 (2019)
- [63] Blennow, K., Chen, C., Cicognola, C., Wildsmith, K.R., Manser, P.T., Bohorquez, S.M.S., Zhang, Z., Xie, B., Peng, J., Hansson, O., Kvartsberg, H., Portelius, E., Zetterberg, H., Lashley, T., Brinkmalm, G., Kerchner, G.A., Weimer, R.M., Ye, K., Höglund, K.: Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. *Brain* **143**(2), 650–660 (2020)

- [64] Barthélemy, N.R., Fenaille, F., Hirtz, C., Sergeant, N., Schraen-Maschke, S., Vialaret, J., Buée, L., Gabelle, A., Junot, C., Lehmann, S., Becher, F.: Tau protein quantification in human cerebrospinal fluid by targeted mass spectrometry at high sequence coverage provides insights into its primary structure heterogeneity. *J. Proteome Res.* **15**(2), 667–676 (2016)
- [65] Horie, K., Barthélemy, N.R., Sato, C., Bateman, R.J.: CSF tau microtubule binding region identifies tau tangle and clinical stages of alzheimer’s disease. *Brain* **144**(2), 515–527 (2021)
- [66] Trinkaus, V.A., Riera-Tur, I., Martínez-Sánchez, A., Bäuerlein, F.J.B., Guo, Q., Arzberger, T., Baumeister, W., Dudanova, I., Hipp, M.S., Hartl, F.U., Fernández-Busnadiego, R.: In situ architecture of neuronal α -Synuclein inclusions. *Nat. Commun.* **12**(1), 2110 (2021)
- [67] Leuzy, A., Chiotis, K., Lemoine, L., Gillberg, P.-G., Almkvist, O., Rodriguez-Vieitez, E., Nordberg, A.: Tau PET imaging in neurodegenerative tauopathies-still a challenge. *Mol. Psychiatry* **24**(8), 1112–1134 (2019)
- [68] Tagai, K., Ono, M., Kubota, M., Kitamura, S., Takahata, K., Seki, C., Takado, Y., Shinotoh, H., Sano, Y., Yamamoto, Y., Matsuo, K., Takuwa, H., Shimojo, M., Takahashi, M., Kawamura, K., Kikuchi, T., Okada, M., Akiyama, H., Suzuki, H., Onaya, M., Takeda, T., Arai, K., Arai, N., Araki, N., Saito, Y., Trojanowski, J.Q., Lee, V.M.Y., Mishra, S.K., Yamaguchi, Y., Kimura, Y., Ichise, M., Tomita, Y., Zhang, M.-R., Suhara, T., Shigeta, M., Sahara, N., Higuchi, M., Shimada, H.: High-Contrast in vivo imaging of tau pathologies in alzheimer’s and Non-Alzheimer’s disease tauopathies. *Neuron* **109**(1), 42–588 (2021)
- [69] Shi, Y., Murzin, A.G., Falcon, B., Epstein, A., Machin, J., Tempest, P., Newell, K.L., Vidal, R., Garringer, H.J., Sahara, N., Higuchi, M., Ghetti, B., Jang, M.-K., Scheres, S.H.W., Goedert, M.: Cryo-EM structures of tau filaments from alzheimer’s disease with PET ligand APN-1607. *Acta Neuropathol.* **141**(5), 697–708 (2021)
- [70] Pavlova, A., Cheng, C.Y., Kinnebrew, M., Lew, J., Dahlquist, F.W., Han, S.: Protein structural and surface water rearrangement constitute major events in the earliest aggregation stages of tau. *Proc. Natl. Acad. Sci. U. S. A.* **113**(2), 127–136 (2016)

8 Figures




Fig. 1 (a) Schematic of the cellular amplification of CBD and PSP patient samples, followed by cell-free seeding of recombinant Tau187 using cell-passaged seeds. The inset shows the tau constructs including full-length 2N4R tau (FL, in green), K18 (in orange), and Tau187 (in blue). (b) Schematics of the published CBD fold (PDB ID 6TJO) [21] and PSP fold (PDB ID 7P65) [19] with the three selected spin-label pairs: 351 & 373, 334 & 360, and 340 & 378. The mean distances between the spin-label pairs were measured directly in the PDB files, and are labeled within this figure. (c) Theoretical distance distributions simulated from the published cryo-EM structures of the CBD fold [21] and PSP fold [19] by the RotamerConvolveMD method [36] in the 2-8 nm range for the three spin-labeled pairs. The distance distributions across the spin-label pair at residues 351 & 373 are referred to as $P(r, 351-373)$. The same rule applies to $P(r, 334-360)$ and $P(r, 340-378)$




Fig. 2 (a) Representative images of Tau4RD*LM-YFP cells and Tau3RD*VM-YFP cells infected with CBD and PSP patient samples. YFP is shown in green. (Scale bar, 50 μ m). (b) Quantification of cell infection. * = $P < 0.05$. (c) Lysates collected in RIPA buffer from naïve HEK293T cells, Tau3RD*VM-YFP cells, Tau4RD*LM-YFP cells, and Tau4RD*LM-YFP cells stably infected with CBD or PSP tau prions were analyzed for the presence of the tau-YFP fusion protein by Western blot using the GFP primary antibody (top blot). Vinculin (bottom blot) is shown as a loading control.




Fig. 3 (a) ThT fluorescence of tau fibrillization induced by heparin (green), or cell-passaged seeds (lysates) from CBD (pink) or PSP (blue) patient samples. The lysate-seeded aggregation generated a relatively low maximum ThT; an enlarged curve is shown in the inset. Tau187 (25 μ M) was mixed with stoichiometric amounts of heparin (8.25 μ M, 17% by mass) or cell-passaged lysates [either 5% (lighter-color lines) or 15% by mass (darker-colored lines)] and was aggregated in the presence of ThT at 37 °C. (b) Representative negative stain TEM of heparin-induced fibril and lysate-seeded fibrils (scale bar, 500 nm.), with magnified images shown to the right (scale bar, 100 nm.). (c) Representative images of Tau4RD*LM-YFP cells infected with monomeric Tau187, heparin-induced fibril, and lysate-seeded fibrils. While all fibrils induced tau-YFP aggregation, monomeric Tau187 had no effect on the cells. YFP is shown in green. (Scale bar, 50 μ m.) (d) Quantification of tau-YFP aggregation following infection with Tau187 monomer, heparin-induced fibrils, or lysate-seeded fibrils in Tau3RD*VM-YFP cells (left) and Tau4RD*LM-YFP cells (right). *** = $P < 0.001$




Fig. 4 Intra-molecular DEER distance distribution, $P(r)$, measured for heparin fibrils (green, solid), CBD lysate-seeded fibrils (pink, solid), and PSP lysate-seeded fibrils (blue, solid). Expected distances (dotted curves) were simulated from the published cryo-EM structures of the CBD fold (PDB: 6TJO; pink, dotted) and PSP fold (PDB: 7P65; blue, dotted) [19, 21] by the RotamerConvolveMD method [36] and are illustrated on the schematic view of these folds in Fig. 1. Three spin-label pairs were measured and simulated for (a) residues 351 & 373, (b) residues 334 & 360, and (c) residues 340 & 378. Replicates are shown in SI Figures, Fig. S6 to Fig. S8